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INTRODUCTION: Performance variation among PCR systems in detecting Toxoplasma gondii has been extensively reported and 
associated with target genes, primer composition, amplification parameters, treatment during pregnancy, host genetic susceptibility 
and genotypes of different parasites according to geographical characteristics. 
PATIENTS: A total of 467 amniotic fluid samples from T. gondii IgM- and IgG-positive Brazilian pregnant women being treated 
for 1 to 6 weeks at the time of amniocentesis (gestational ages of 14 to 25 weeks). 
METHODS: One nested-B1-PCR and three one-round amplification systems targeted to rDNA, AF146527 and the B1 gene were 
employed. 
RESULTS: Of the 467 samples, 189 (40.47%) were positive for one-round amplifications: 120 (63.49%) for the B1 gene, 24 
(12.69%) for AF146527, 45 (23.80%) for both AF146527 and the B1 gene, and none for rDNA. Fifty previously negative one-
round PCR samples were chosen by computer-assisted randomization analysis and re-tested (nested-B1-PCR), during which nine 
additional cases were detected (9/50 or 18%). 
DISCUSSION: The B1 gene PCR was far more sensitive than the AF146527 PCR, and the rDNA PCR was the least effective 
even though the rDNA had the most repetitive sequence. Considering that the four amplification systems were equally affected 
by treatment, that the amplification conditions were optimized for the target genes and that most of the primers have already been 
reported, it is plausible that the striking differences found among PCR performances could be associated with genetic diversity in 
patients and/or with different Toxoplasma gondii genotypes occurring in Brazil. 
CONCLUSION: The use of PCR for the diagnosis of fetal Toxoplasma infections in Brazil should be targeted to the B1 gene when 
only one gene can be amplified, preferably by nested amplification with primers B22/B23. 
KEYWORDS: Toxoplasma gondii; Toxoplasmosis; Congenital infection; PCR; Molecular diagnosis. 
INTRODUCTION
Toxoplasmosis causes an endemic worldwide infection 
that is asymptomatic in the majority of patients, with the 
exception of pregnant women and immunosuppressed 
individuals. Primary maternal Toxoplasma infection 
exposes the fetus to the risk of parasite transmission, 
leading to severe congenital toxoplasmosis, depending 
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on host susceptibility, date of transmission, prescription 
of anti-parasite treatment, parasite burden and parasite 
genotype.1-5 Although conventional laboratory diagnosis 
is still based on serologic parameters such as the presence 
of IgM and IgG anti-Toxoplasma and parasite isolation in 
mice or culture, the polymerase chain reaction (PCR) has 
been performed since the 1990s in an attempt to improve 
laboratory diagnosis sensitivity. There is, however, no 
consensus regarding the most effective amplification system 
for this purpose.6-13 The efficiency of PCR targets was tested 
in controlled studies, and the disease has been associated 
with three main clonal lineages of T. gondii, with type 
I corresponding to more pathogenic strains and types II 
and III to less pathogenic ones. There is a high prevalence 
of genotype II in congenital infection, which, has not yet 
been described in South American human infections.14 The 
present study aimed to analyze the performance of three 
one-round PCRs targeted to rDNA, AF146527 and the B1 
gene in the amniotic fluid of 467 pregnant Brazilian women 
who seroconverted during the first or early second trimester 
of pregnancy and were treated for acute toxoplasmosis until 
labor. Furthermore, the performance of a nested-B1-PCR 
was evaluated in 50 previously negative T. gondii one-
round amplifications. 
PATIENTS AND METHODS
PATIENTS: This research was approved by the 
Institutional Ethics Committee (CAPPesq protocol 
number 624/2005). A total of 467 pregnant women from 
public hospitals of São Paulo, Brazil were submitted to 
amniocentesis under ultrasound guidance during the second 
trimester (14-25 weeks of gestation, corresponding to 
probable seroconversion taking place between the 10th and 
21st weeks). Inclusion criteria were based on the serological 
evidence of recent Toxoplasma infection (presence of positive 
IgM and significant titers of IgG anti-Toxoplasma, evaluated 
by means of commercial immuno-enzymatic or immuno-
quimioluminescent tests or immuno-fluorimetry, depending 
on the local availability). Exclusion criteria included 
inadequate amniotic fluid samples either by the mixture with 
blood or meconium or sample insufficiency (less than 5 ml 
of amniotic fluid collected from the 14th week). Of the 467 
patients, 388 (83.08%) were on spiramicin and 79 (16.92%) 
were on sulfadiazine therapy, which began immediately after 
diagnostic serology, performed with commercial kits15 1 to 
6 weeks before amniocentesis. The decision regarding the 
prescription of either spiramicin or sulfadiazine was made on 
the basis of gestational age, i.e., those who started treatment 
before the 18th week received spiramicin and, in the minority 
of cases, sulfadiazine was used after the 18th week. Patients 
were informed of amniocentesis risks and the nucleic acid 
procedures and consented with all subsequent testing. 
DNA EXTRACTION, AMPLIFICATION AND 
DETECTION: DNA from amniotic fluid samples was 
obtained according to a previously described salting-out 
protocol16. DNA concentration was estimated by means 
of UV spectrophotometry at 260 nm (DU-70, Beckman). 
PCR assays were performed in 50 µLL of total volume (MJ 
Research PT-150 minicycler) containing approximately 
100 ng of genomic DNA from amniotic fluid samples, 
100 mM Tris-HCl and 500 mM KCl, 2.5 units of Taq 
DNA polymerase (Amersham Biotech, USA), 200 µM 
dNTP (Invitrogen, USA), 1.5 mM MgCl2 and 0.4 µM for 
each of the primers (IDT- synthesized by Prodimol, Belo 
Horizonte, Brazil). The PCR products were detected in 2% 
ethidium-bromide-stained agarose gels (Sigma, USA) or 
2:1 nusieve-agarose gels (FMC – Sigma) in a horizontal 
electrophoresis apparatus (Horizon H58, Life Technologies, 
USA). In each experiment, a negative control composed of 
either sterile water instead of genomic DNA or DNA from 
a non-infected individual was tested. A positive control was 
also employed (Toxoplasma gondii RH strain DNA). Prior to 
specific Toxoplasma amplifications, all DNA samples were 
amplified with β-actin primers17 to ensure the inexistence of 
amplification inhibitors. The amplification parameters of the 
PCR systems are described in table 1.
RESULTS
A total of 467 women, aged 18-35 years, were enrolled 
in the present study. All had seroconverted during the 
late first or early second trimester, 321 (66.8%) were 
in their second pregnancy and 299 (64.0%) had a fetal 
ultrasound examination. Only three women (1.0%) presented 
abnormalities, according to the attendant physicians. Anti-
Toxoplasma IgG avidity tests were reported in only 32 
women (6.85%), and tests were performed with four different 
in-house methods, showing eight patients with low avidity, 
12 with high avidity IgG samples and 12 inconclusive tests 
(with a recommendation to repeat the test after two weeks). 
One-round amplifications. The β-actin fragment was 
amplified from all 467 DNA samples from the amniotic 
fluid specimens, thus confirming the lack of inhibitors. Of 
the specific Toxoplasma DNA amplifications, 189 (40.5%) 
samples were positive for at least one of the one-round 
PCR systems: 120/189 (63.5%) for the B1 gene, 24/189 for 
AF146527 (12.7%) and 45/189 (23.8%) for both B1 and 
AF146527. None of the samples were positive for rDNA 
(0/189). 
Nested-B1-PCR. Fifty of the 278 amniotic fluid samples 
that had negative results in the three one-round PCRs were 
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chosen by computer-assisted randomization analysis(20) (www.
random.org) and were re-tested by a nested PCR, targeting 
the B1 gene. Random numbers are useful for a variety of 
purposes, including the selection of random samples from 
larger data sets. This double-round amplification detected nine 
additional positive cases (9/50 or 18%). 
DISCUSSION
This study has limitations due to the lack of clinical 
data, accurate serological results (in particular, an IgG 
avidity test) and high-quality descriptions of fetal ultrasound 
abnormalities. In a recent study,21 553 serum samples 
from pregnant women whose dates of infection had been 
determined as well as 50 samples from immunosuppressed 
patients were tested for IgG avidity by means of a novel 
immunoassay. The authors concluded that this novel avidity 
test (Vidas) was helpful in ruling out that infection had 
occurred within the past four months. Unfortunately, the 
anti-Toxoplasma IgG avidity test was reported in a minority 
of 32 patients (6.85%) in our study, invalidating efforts to 
analyze our data with respect to the literature. 
Another point that merits discussion is the follow-up of 
newborns until the age of 12 months with repeated anti-T. 
gondii IgM and IgG measurements. Although this procedure 
is highly recommended, these measurements were obtained 
in only 84 children belonging to the first part of the study. 
Nevertheless, the 467 amniotic fluid samples reported 
here constitute the most representative South American 
cohort analyzed thus far, although the only inclusion 
criterion adopted in our study was the documentation of 
seroconversion to T. gondii during pregnancy. 
There is a general concern regarding the significant 
variability found in amplification systems used to detect 
Toxoplasma gondii DNA in different types of biological 
samples. Guy et al. (1996)22 performed a multi-center 
study comprised of five European centers that reported 
amniotic fluid samples containing limiting dilutions of 
tachyzoites that varied from 10 to zero. They reported a 
lack of positive sample detection as well as false positives. 
In another European multi-center study involving fifteen 
laboratories, Pelloux et al. (1997)23 concluded that there was 
great heterogeneity among PCR protocols and comparative 
performances, as only nine of the fifteen laboratories 
succeeded in amplifying the equivalent of one parasite, two 
were unable to detect any of the positive samples, and four 
laboratories had false-positive results. More recently, Kaiser 
et al. (2007)24 studied the performance of 33 laboratories 
from 17 different countries. Only 42.1% of the samples were 
correctly identified, while two or more mistakes occurred 
in 36.8% of the centers. The lowest parasite concentration, 
corresponding to five tachyzoites, was not identified by 
39.5% of the laboratories. In-house techniques were used in 
84.2% of the laboratories, and a commercial kit was used in 
the remaining 15.8%. False-positive results occurred in two 
laboratories (6.06%). 
Because amplification techniques used to detect 
Toxoplasma DNA by PCR are not standardized and because 
Table 1 - Description of the four PCR systems used in the present study
Target gene Primer composition Annealing Cycles Amplicon Reference
B1 JW 63 - sense 
5’-GCACCTTTCGGACCTCAACAACCG-3’
JW 62 - anti-sense
5’- TTCTCGCCTCATTTCTGGGTCTAC-3’ 
550C 40 286 bp Pelloux et al. 18
rDNA rtg1- sense
5’- GGCATTCCTCGTTGAAGATT-3’
rtg2 - anti-sense
5’- CCTTGGCCGATAGGTCTAGG-3’
580C 40 88 bp Bretagne et al. 7
AF146527 AF146527 - sense 
5’- CTGCAGGGAGGAAGACGAAAGTT-3’
AF146527- anti-sense
5’- CTGCAGACACAGTGCATCTGGAT-3’ 
550C 40 529 bp Homan et al. 19
B1 (nested) JW 63 - sense (first round)
5’-GCACCTTTCGGACCTCAACAACCG-3’
JW 62 - anti-sense (first round)
5’- TTCTCGCCTCATTTCTGGGTCTAC-3’
B22m - 2nd PCR - sense (second round)
5’- AACGGGCGAGTAGCACCTGAGGAGA-3’ 
B23m - 2ndPCR - anti-sense (second round)
5’-TGGGTCTACGTCGATGGCATGACAACT-3’
550C
620C
40
25
286 bp
115 bp
Pelloux et al. 18
Hohlfeld et al. 6
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there is no consensus on the best protocol to use,6-13,15 
the present study has evaluated the performance of three 
one-round amplification systems (B1 gene, AF146527, 
rDNA) to detect Toxoplasma gondii DNA in 467 amniotic 
fluid samples. A total of 189 samples (40.47%) yielded 
positive results using at least one of the three one-round 
PCR systems, which is in agreement with the expected 
transmission rate during the second trimester of gestation.15 
It is also important to note that the majority of the primers 
used in our study are among the most tested in the literature, 
in particular, the B22/B23 primers for the B1 gene. 
According to previous studies, the three one-round PCR 
systems employed are able to detect the equivalent of one 
to ten parasites,6,7,18,19 a finding confirmed in our facilities 
in spiked samples and limiting dilution series. A second 
round of amplification should therefore not be necessary in 
order to attain an adequate sensitivity. Results of the first 
part of our study, however, have suggested the opposite. The 
three amplification systems employed, even though they 
were targeting repetitive sequences (rDNA has hundreds 
of copies in one parasite genome, AF146527 has between 
200 and 300 copies and the B1 gene has 35 copies per 
genome), showed significant performance differences and 
inadequate sensitivity (only 78.6%) when using clinical, 
ophthalmologic, radiological and serological follow-up of 
84 children (from PCR-positive pregnancies) until the age of 
12 months25 as diagnostic criteria. Unfortunately, we did not 
have access to data concerning the other 383 cases, because 
either the mothers gave birth in different hospitals or the 
neonates were included in other studies. 
It is important to note that the rDNA PCR did not succeed 
in amplifying any of the 467 amniotic fluid samples tested, 
although this method has been employed in previous studies 
carried out in our laboratory to diagnose cases of ocular 
toxoplasmosis and congenital infection (data not shown). 
The use of a nested-B1-PCR increased the sensitivity in the 
present study, as we found nine additional positive cases 
among the 278 initially negative one-round PCRs. This 
indicates that although theoretically not necessary, a second 
round of amplification can be helpful, especially when 
treated patients are being evaluated2. These results are most 
likely due to a reduction in parasite burden. 
Although it is logical that a nested amplification should 
always be more sensitive than one-round systems and that 
the detection should be more sensitive for more repetitive 
DNA sequences, a series of studies have found discordant 
results. Homan et al.19 described the AF146527 sequence, 
which is repeated 200-300 times, reporting that amplification 
systems derived from AF146527 were more sensitive than 
those of the B1 gene. Our results were inconsistent with 
these findings. Jones et al.8 analyzed aqueous humor samples 
by means of three different PCR systems with primers for 
the B1 gene, SAG1 and rDNA. The first two systems were 
nested amplifications, whereas the rDNA PCR was a one-
round PCR. They concluded that the B1 gene PCR was more 
sensitive than the other two amplification systems, which is 
consistent with our results, although we did not test SAG1. 
Filisetti et al.10 analyzed 83 samples from 44 newborns with 
suspicion of congenital toxoplasmosis by means of rDNA, 
B1 gene and AF146527 amplification. Unlike our study, 
they concluded that the three systems were equivalent and, 
surprisingly, that they were not more sensitive than the 
isolation of the parasite after mice inoculation. Buchbinder 
et al.9 analyzed 11 patients with congenital toxoplasmosis 
by means of real time PCR with primers for the B1 gene 
and SAG1. They were able to detect the equivalent of 10 
parasites and concluded that the two systems were equally 
sensitive. Jalal et al.12 tested eight amniotic fluid samples, 
two CSF samples, four vitreous humor samples and six 
biopsies. The amplification systems tested were based on 
the B1 gene using one-round PCR, or nested amplification 
followed by hybridization in microtitration plaques (enzyme 
immunoassay). Unlike our study, they found that it was 
not beneficial to perform a nested amplification or a PCR 
followed by hybridization because there was no sensitivity 
gain. In an interesting report, Chabbert et al.11 tested two 
amplification systems using two different sets of primers, 
both for the B1 gene (B22/B23 and T1-T4). They concluded 
that the B22/23 system was more sensitive than the T1-T4 
system, even though all of the primers were chosen within 
the B1 gene sequence. In our study, we also used the so-
called “more sensitive B1 gene primers” B22/B23 in the 
nested amplification and have corroborated the sensitivity 
gain. More recently, Nagy et al.13 analyzed 64 amniotic fluid 
samples using four different amplification methods: one 
conventional PCR, one PCR-RFLP, and two real time PCR 
systems with different detection methods. Although they 
claimed that the two real time PCR systems were the most 
sensitive, they concluded that all four systems were able to 
detect as few as five parasites and were therefore considered 
to be suitable for molecular diagnosis of congenital 
infections. 
Finally, HLA-class II genes may modify the outcome of 
Toxoplasma gondii infection1 in hosts with different genetic 
features. With respect to parasites, atypical or recombinant 
genotypes among Toxoplasma isolates from different 
countries and continents leading to DNA polymorphisms 
at the exact site of primer-target DNA hybridization could 
also decrease amplification performance. This heterogeneity 
might occur between Toxoplasma isolates infecting humans 
and animals in Brazil as well as other South American 
countries14,26-29 and could at least partially explain why 
175
CLINICS 2009;64(3):171-6 Variation among PCR systems in Brazilian samples
Okay TS et al.
the B1 gene PCR was significantly more sensitive than 
the AF146527 system in the present study. and the most 
repetitive sequence, the rDNA, did not amplify any of 
the 467 amniotic fluid samples tested. Further studies 
are needed to determine whether Brazilian women are 
genetically distinct from other populations as well as whether 
Toxoplasma gondii genotypes of amniotic fluid samples in 
Brazil are different from those described in Europe, USA 
and other South American countries. 
We conclude that the use of PCR for the diagnosis of 
fetal Toxoplasma infection in Brazil should be targeted to the 
B1 gene when limited to only one gene, preferably by nested 
amplification with the B22/B23 primers. 
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